Compare Cytokinetics Inc (CYTK) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Levi Strauss & Co. — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Levi Strauss & Co. trades at $22.74 (market cap $9.09B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 2.71% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | LEVI | |
|---|---|---|
Market Cap | $10.78B | $9.09B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $25.53 |
52-Week Low | $33.23 | $17.92 |
Enterprise Value | $10.88B | $10.40B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Levi Strauss (LEVI) trades at $24.4, up 0.39% on the day, with a bullish fundamental backdrop including strong earnings beats and a 77.78% analyst buy rating. The stock shows a bearish technical signal overall, with neutral RSI readings and key resistance at $25. Recent news highlights a cybersecurity breach disclosed on August 7, 2026, but the company's direct-to-consumer digital strategy continues to drive growth.
Outlook remains positive with a consensus price target of $27.88, implying 14.3% upside, supported by robust profitability and raised 2026 guidance. Risks include recent cybersecurity issues, tariff pressures, and execution challenges in a competitive apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
